HOUSTON--(BUSINESS WIRE)--Sep 11, 2018--AngioSoma (OTC: SOAN) announces today the development of a new and improved version of its popular StemStrength™ formula. Original StemStrength™ was designed for men only but AngioSoma is excited to reveal the new StemStrength™ will be for both Women and Men, plus it will come in an AM and PM formulation. The new product will be offered through AngioSoma’s retail brand, SomaCeuticals (soma-ceuticals.com).

This offering of four different products reaches a wider audience and optimizes the positive physical effects of an already successful product. The timing of supplementation is important since the body needs different nutrients in the morning than in the evening. The morning formula excels at creating energy, focus and power for the day’s work ahead. The evening formula maximizes your recovery and helps your enjoy a restful sleep.

The active ingredients have been changed to be specific for men and women, morning and evening. The new formulation is a dramatic improvement from the old supplement because each of the four products are focused on women for morning and night and for men morning and night

The launch of this new product line is projected to be within 6 weeks. “We pride ourselves on innovating new and improved nutraceuticals to consumers and iterating when new advancements are made available,” said Alex Blankenship, President. “We couldn’t be more excited with the improvements made to this product suite, the great experiences our customers have with our products and enhanced performance this product brings to the market.”

AngioSoma is excited to continue to innovate for its customers across the spectrum of health-related products. Our goal is to get results and improve lives and we believe this new enhanced formula is the next big step for us towards that goal.

Our products can be found at: Soma-Ceuticals.com

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. ( https://angiosoma.com ), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaCeuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005249/en/

CONTACT: AngioSoma, Inc.

Alex Blankenship

investors@AngioSoma.com

KEYWORD: UNITED STATES NORTH AMERICA TEXAS

INDUSTRY KEYWORD: HEALTH FITNESS & NUTRITION OTHER HEALTH

SOURCE: AngioSoma, Inc.

Copyright Business Wire 2018.

PUB: 09/11/2018 06:30 AM/DISC: 09/11/2018 06:30 AM

http://www.businesswire.com/news/home/20180911005249/en